Join to access to all OVN content. Join for Free
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs
FDA labeling format PLR format oncology drugs FDA

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs


Share This Article


Summary

  • The FDA conducts independent reviews of scientific data to ensure the safety and efficacy of investigational drug products.
  • FDA-approved product labeling is a highly trusted source of information for approved drug use.
  • FDA approval is only the beginning of a drug's lifecycle, with ongoing clinical experiences spanning decades.
  • Some companies may not update FDA-approved labeling with new data, other than safety information, due to lack of incentives.
  • Ensuring adequate directions for use in product labeling is crucial for all drugs, particularly older therapies used in standard combination regimens.
  • Project Renewal is an FDA Oncology Center of Excellence pilot program designed to review literature and update FDA-approved product labeling.
  • The program collaborates with the clinical and scientific oncology communities to generate reports that support labeling updates.
  • The article discusses Project Renewal's process for identifying and assessing literature, and its effort to engage the oncology community.

The FDA-approved product labeling is a summary of information verified during FDA's independent, unbiased review of pharmaceutical quality, nonclinical and clinical pharmacology, and clinical study data. In 2006, the Physician Labeling Rule (PLR) was published, creating a consistent content and format for product labeling, including highlights of prescribing information, a table of contents, and 17 discrete sections intended to improve healthcare providers' ability to locate important prescribing information (Table 1). The most updated version of FDA product labeling for each approved product is available to the public online....  

Click for Source Download PDF version
FDA labeling format, PLR format, oncology drugs, FDA

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs
OVN Avatar The Oncology Nursing Podcast

Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs

Podcast
The Role of MSLs in Achieving Health Equity
Partner Avatar MSL Talk: Tom Caravela, Ariel Katz

The Role of MSLs in Achieving Health Equity

Podcast
How and Why Medical Affairs Can Support Diversity in Clinical Trials
Partner Avatar MSL Talk: Tom Caravela, Brad Atkinson, Brian Wilson, Christina Wright

How and Why Medical Affairs Can Support Diversity in Clinical Trials

Podcast
Compliance 101-Most common issues and MSL-related gray areas
Partner Avatar MSL Talk: Tom Caravela, Jessica McLin, Melody Davis

Compliance 101-Most common issues and MSL-related gray areas

Article
Evaluating External Validity of Oncology Biosimilar Safety Studies
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD

Evaluating External Validity of Oncology Biosimilar Safety Studies

Article
Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021
OVN Avatar Yafang Huanga, Weiyi Xiongb, Jingwei Zhaoa, Wentao Lia, Li Mac, Hao Wua

Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021

Explore OVN